Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one

Patent metadata

Field	Value
Publication number	US-12139490-B2
Application number	US-202217808836-A
Country	US
Kind code	B2
Filing date	Jun 24, 2022
Priority date	Mar 12, 2007
Publication date	Nov 12, 2024
Grant date	Nov 12, 2024

Abstract

The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, such as the compound of Formula 2J, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, and as further defined herein.

First claim

What is claimed is:

1. A process for preparing a compound of Formula 1J or Formula 2J:

or a pharmaceutically acceptable salt form thereof,
wherein:
R 1 is:

each R 5 is independently H;
R 6a is H;
R 6b is H;
R 7 is H;
R 8 is H;
R 9 is H;
X is N;
R 10 is CH 3 ;
k is 1;
m is 1; and
n is 1;

wherein the process comprises the following steps:
(1)N-alkylating the free base form of a compound of Formula 1I or Formula 2I:

or a salt form thereof,
wherein:
each R 5 is independently H;
R 6a is H;
R 6b is H;
R 7 is H;
R 8 is H;
R 9 is H;
X is N;
R 10 is CH 3 ;
k is 1;
m is 1; and
n is 1;

with a compound of the following formula:
G-Z-R 13 ,

wherein:
G is

Z is —C(O)—; and
R 13 is

in the presence of a base selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), and (k):
(a) an amine base selected from the group consisting of ammonia, triethylamine, N,N′-diisopropylethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), and 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU);
(b) an alkali metal hydride selected from the group consisting of lithium hydride, sodium hydride, and potassium hydride;
(c) an alkali metal alkoxide selected from the group consisting of lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, NaOAr, and KOAr, wherein Ar is aryl;
(d) an alkali metal carbonate selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, and cesium carbonate;
(e) an alkaline earth metal carbonate selected from the group consisting of magnesium carbonate, calcium carbonate, and barium carbonate;
(f) an alkali metal bicarbonate selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, and cesium bicarbonate;
(g) an alkaline earth metal bicarbonate selected from the group consisting of magnesium bicarbonate, calcium bicarbonate, and barium bicarbonate;
(h) an alkali metal hydroxide selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide;
(i) an alkaline earth metal hydroxide selected from the group consisting of magnesium hydroxide, calcium hydroxide, and barium hydroxide;
(j) an alkali metal phosphate selected from the group consisting of lithium phosphate, sodium phosphate, potassium phosphate, and cesium phosphate; and
(k) an alkaline earth metal phosphate selected from the group consisting of magnesium phosphate, calcium phosphate, and barium phosphate;

to provide the compound of Formula 1J or Formula 2J above; and
(2) when the process provides a pharmaceutically acceptable salt form of the compound of Formula 1J or Formula 2J above, optionally reacting the free base form of the compound of Formula 1J or Formula 2J provided in step (1) above with an acid selected from the group consisting of acetic acid, phenylacetic acid, trifluoroacetic acid, ascorbic acid, benzoic acid, 2-acetoxybenzoic acid, citric acid, ethanedisulfonic acid, fumaric acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, hydroxymaleic acid, malic acid, methanesulfonic acid, nitric acid, oxalic acid, pamoic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tartaric acid, and toluenesulfonic acid, in the presence of water or an organic solvent selected from the group consisting of 3-pentanone, dioxane, diethyl ether, ethanol, ethyl acetate, isopropanol, acetonitrile, and toluene, or a combination thereof, to provide a pharmaceutically acceptable salt form of the compound of Formula 1J or Formula 2J.

2. The process according to claim 1 , wherein the compound of Formula 1I or Formula 2I is in the free base form.

3. The process according to claim 1 , wherein the compound of Formula 1I or Formula 2I is in a salt form.

4. The process according to claim 1 , wherein the compound of Formula 1I or Formula 2I is in a salt form selected from the group consisting of a hydrochloric acid salt form, a phosphoric acid salt form, a sulfuric acid salt form, and a trifluoracetic acid salt form.

5. The process according to claim 1 , wherein the compound of Formula 1I or Formula 2I is in a hydrochloric acid salt form.

6. The process according to claim 1 , wherein G is:

7. The process according to claim 1 , wherein G is:

8. The process according to claim 1 , wherein the base is selected from the group consisting of (a), (d), (e), (f), (g), (h), and (i):
(a) an amine base selected from the group consisting of ammonia, triethylamine, N,N′-diisopropylethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), and 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU);
(d) an alkali metal carbonate selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, and cesium carbonate;
(e) an alkaline earth metal carbonate selected from the group consisting of magnesium carbonate, calcium carbonate, and barium carbonate;
(f) an alkali metal bicarbonate selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, and cesium bicarbonate;
(g) an alkaline earth metal bicarbonate selected from the group consisting of magnesium bicarbonate, calcium bicarbonate, and barium bicarbonate;
(h) an alkali metal hydroxide selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide; and
(i) an alkaline earth metal hydroxide selected from the group consisting of magnesium hydroxide, calcium hydroxide, and barium hydroxide.

9. The process according to claim 8 , wherein the base is selected from the group consisting of (a), (d), (e), (f), (g), (h), and (i):
(a) an amine base selected from the group consisting of ammonia, triethylamine, N,N′-diisopropylethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), and 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU);
(d) an alkali metal carbonate selected from the group consisting of sodium carbonate, potassium carbonate, and cesium carbonate;
(e) an alkaline earth metal carbonate selected from the group consisting of magnesium carbonate, calcium carbonate, and barium carbonate;
(f) an alkali metal bicarbonate selected from the group consisting of sodium bicarbonate, potassium bicarbonate, and cesium bicarbonate;
(g) an alkaline earth metal bicarbonate selected from the group consisting of magnesium bicarbonate, calcium bicarbonate, and barium bicarbonate;
(h) an alkali metal hydroxide selected from the group consisting of sodium hydroxide, potassium hydroxide, and cesium hydroxide; and
(i) an alkaline earth metal hydrox

Assignees

• Intra Cellular Therapies Inc

Inventors

• Tomesch John Charles
• Li Peng
• Yao Wei
• Zhang Qiang
• Beard James David
• Thompson Andrew S
• Cheng Hua
• Wennogle Lawrence P

Classifications

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07D471/14

  Ortho-condensed systems · CPC title

• C07D471/12

  in which the condensed system contains three hetero rings · CPC title

• C07D471/02

  in which the condensed system contains two hetero rings · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title